Proteomic study of benign and malignant pleural effusion

Abstract

This model is suitable to discriminate benign and malignant pleural effusion and CARD9 can be used as a new peptide biomarker.

Caspase Recruitment Domain Containing Protein 9 Suppresses Non-Small Cell Lung Cancer Proliferation and Invasion via Inhibiting MAPK/p38 Pathway

“…Research on the role of CARD9 in malignant diseases, especially the role of CARD9-mediated immunity or inflammation in tumors has been a hotspot nowadays. Contrary to previous findings regarding the increase of CARD9 in tumors, our previous research found that CARD9 was decreased in malignant pleural effusion compared with benign pleural effusion, indicating an interesting role of CARD9 in lung cancer [9]. In this study, both TCGA database and our clinical cohort showed the mRNA and protein level of CARD9 were lower in NSCLC tissues than that in adjacent normal lung tissues.…”

“…However, CARD9 appears to function differently in lung cancer. Our previous research on the difference of protein profiles of the benign and malignant pleural effusion by proteomics technology found that CARD9 was decreased in malignant pleural effusion, and the mechanism was not clear [9]. In the latest study of CARD9 in lung cancer, Qu et al [10] reported that CARD9 suppressed lung cancer development by inhibiting the expansion of myeloid-derived suppressor cells (MDSCs) and indoleamine 2,3-dioxygenase (IDO) production.…”

CARD9 as a potential therapeutic target in lung cancer

“…We previously summarized the clinical significance of CARD9 in a variety of tumor types (Table 1) including hepatocellular carcinoma, intestinal carcinoma, gastric carcinoma, kidney carcinoma, and malignant pleural effusion [16,17]. These studies suggest that high CARD9 expression is associated with tumor progression and poor survival rate [18][19][20][21][22]. However, preclinical studies in tumor-prone mouse models indicate that CARD9 plays a dual role in the carcinogenic process as it exhibits both a pro-tumor and/or anti-tumor activity [23][24][25][26].…”

Diagnostic value of soluble B7‐H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion

“…Pleural effusion is a commonly clinical manifestation and even appears as an initial symptom. It is still a clinical challenge to identify the malignant pleural effusion (MPE) or benign pleural effusion (BPE) due to a series of etiology agents ranging from tuberculosis to tumors . Because MPE could reduce the overall survival, it was vitally crucial to accurately distinguishing malignant from benign pleural effusion in order to manage MPE timely.…”

“…It is still a clinical challenge to identify the malignant pleural effusion (MPE) or benign pleural effusion (BPE) due to a series of etiology agents ranging from tuberculosis to tumors . Because MPE could reduce the overall survival, it was vitally crucial to accurately distinguishing malignant from benign pleural effusion in order to manage MPE timely. The gold diagnosis criteria for MPE including pleural biopsy and exfoliative cytologic pathology examinations could reach up to an average sensitivity 60%; however, these conventionally diagnostic methods were still inadequate or sometimes invasive .…”